This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mallinckrodt Gains on Opioid Settlement, Beats on Q4 Earnings
by Zacks Equity Research
Mallinckrodt (MNK) signs a $1.6-billion agreement for its ongoing opioid litigation and reports better-than-expected Q4 results.
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Morgan Stanley, Sinopec, American Electric Power and Kinder Morgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Morgan Stanley, Sinopec, American Electric Power and Kinder Morgan
Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.
Sanofi Plans Spin-Off of API Unit Into a European Company
by Zacks Equity Research
Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.
Halozyme (HALO) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports wider-than-expected loss and misses revenue estimates in fourth-quarter 2019. Shares down.
Top Research Reports for Johnson & Johnson, Morgan Stanley & Sinopec
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Morgan Stanley (MS) and Sinopec (SNP).
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
3 Best Drugmakers That Are Immune to Coronavirus Fright
by Manaswita Ghosh Dutta
The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.
Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.
Glaxo Underperforms Industry in a Year: What's in Store?
by Zacks Equity Research
Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.
J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.
J&J Files Application for Darzalex Label Expansion With FDA
by Zacks Equity Research
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up
by Zacks Equity Research
AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down
by Zacks Equity Research
Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.
Regeneron Expands Agreement to Develop Coronavirus Therapy
by Zacks Equity Research
Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.
Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.
Theravance Pipeline Strong, Dependence on Yupelri a Concern
by Zacks Equity Research
Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.